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ABSTRACT (272/250 words, Text 1459/1500 characters, without abbreviations,  
subheadings,  references) 
 
The incidence of nephrolithiasis (NL) continues to rise. However, its causes and 
mechanisms are not well understood. Previously, we revealed that a monogenic cause 
could be detected in 11.4% of individuals with adult-onset NL or nephrocalcinosis (NC) 
and in 16.7-20.8% of individuals with onset before 18 years of life using gene panel 
sequencing of 30 known genes. To overcome the limitation of panel sequencing being 
restricted to 30 genes, we here utilized whole exome sequencing (WES) rather than 
panel sequencing   in 41 families, who presented before age 25 yrs with at least 1 renal 
stone or exhibited a renal ultrasound finding of NC to identify the underlying molecular 
genetic cause of disease. In 10 out of 41 (24.3%) families, we detected a monogenic 
causative mutation by WES. We detected a mutation in 5 recessive genes (GRHPR, 
AGXT, SLC12A1, ATP6V1B1, and CLDN19), 1 dominant gene (SLC9A3R1), and 1 
gene (SLC34A1) with both recessive and dominant inheritance. 5 of the 14 different 
mutations were not previously described as disease causing. Median age of onset was 
significantly lower in patients in whom we detected a monogenic cause (3 yrs) vs. those 
without mutation detection (7 yrs) (Z score = 2.49, p < 0.05).  In one family we detected 
a causative mutation in one of 117 genes that may represent phenocopies of NL-
causing genes. In 7/11 patients the genetic diagnosis had specific implications for 
clinical management and primary and secondary prophylaxis.  
Thus, we established WES as an efficient approach towards a molecular genetic 
diagnosis in individuals with NL/NC manifesting before age 25 yrs, and confirmed a 
surprisingly high fraction of individuals (24.3%), in whom a monogenic cause of disease 
may be identified.  
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INTRODUCTION  
Nephrolithiasis (NL) is a highly prevalent condition affecting up to 10% of individuals 
worldwide (Scales, 2012). It is associated with high morbidity, high recurrence rate as 
well as high economic cost (Rule, 2009). Although NL is less common among children 
compared to adults, the incidence of NL and nephrocalcinosis (NC) in the pediatric age 
group has been rising over the past 10 years (Dwyer, 2012). The causes of NL are not 
well understood. Monogenic causes of NL were thought to be rare and restricted to rare 
tubulopathies and genetic syndromes. However, we recently tested the hypothesis that 
monogenic causes of NL account for a high percentage of stone formers, and revealed 
that a causative monogenic mutation can be detected in one of 30 NL genes in 20.8% 
of patients with early-onset of NL before age of 18 yrs (Halbritter, 2015); (Goldfarb, 
2015). We subsequently confirmed the high detection rate of a molecular diagnosis in 
16.7% of early-onset NL in a three-center cohort and found that important therapeutic 
and preventative measures may result from mutation detection (Braun, 2016). These 
previous studies employed exon sequencing in gene panels, rather than whole exome 
sequencing (WES). Because WES offers the opportunity to detect dozens of additional 
genes at a rather low cost and has not been applied to patients with NL, we here 
employ WES in 41 families (54 individuals) with one episode of stone or evidence of NC 
on renal ultrasound before the age of 25 yrs to identify monogenic causes in 30 NL/NC 
known genes, 117 phenocopy genes (30 known tubulopathy genes, 87 ciliopathy 
genes), and 17 hypothesized candidate genes. We confirm the surprisingly high rate of 
monogenic causative mutation detection, study genotype-phenotype correlations, and 
determine that molecular genetic diagnosis allows for finely tailored treatment plans that 
may prevent recurrent disease or delay progression to ESRD.  
 
 
 
 
 
 
5 
 
MATERIALS AND METHODS 
Human subjects. The study was approved by the institutional review board (IRB) of 
Boston Children’s Hospital. After obtaining informed consent clinical data, pedigree 
information, and DNA samples were collected from subjects who had at least one 
occurrence of nephrolithiasis or demonstration of nephrocalcinosis on renal ultrasound 
manifesting before the age of 25 years. Subjects with a potential secondary cause of NL 
such as use of loop diuretics or hyperparathyroidism were excluded from the study. 
Whole exome sequencing was performed in 54 individuals from 41 families. 4 families 
were consanguineous, and 15 families were either sibling cases or with more than one 
affected child. The families were selected for study as follows. We enrolled 339 families 
affected with NL or NC from November 2013 to May 2016 (31 months). Of the 339 
families, 239 families were previously screened by multiplex PCR of a 30-gene panel 
(reported in Halbritter, 2015; Braun, 2016). Of the remaining previously unscreened 100 
families, we examined 41 families by WES. These families were a representative subset 
detected by the criteria of availability of multiple affected family members (15 families), 
or on availability of parents for trio analysis (13 families).  
 
Whole exome sequencing and mutation calling. Whole exome sequencing (WES) 
and variant burden analysis were performed as previously described1, 10, 20. In brief, 
genomic DNA was isolated from blood lymphocytes and subjected to exome capture 
using Agilent SureSelect™  human exome capture arrays (Life technologies™) followed 
by next generation sequencing on the Illumina HighSeq™  sequencing platform. 
Sequence reads were mapped to the human reference genome assembly  
(NCBI build 3/hg19) using CLC Genomics Workbench™ (version 6.5.2) software (CLC 
bio, Aarhus, Denmark). Following alignment to the human reference genome, variants 
were filtered as previously described1, 21 and as summarized in Suppl. Fig. 1. In the first 
step variants with minor allele frequencies (MAF) >1% in the dbSNP (version 144) were 
excluded. In the second step, synonymous variants and intronic variants that were not 
located within splice site regions were excluded. In step 3, variants were evaluated for 
mutations in 30 known NL/NC genes (Suppl. Table 1). In step 4, remaining variants 
were ranked based on their probable impact on protein considering evolutionary 
6 
 
conservation among orthologs across phylogeny, as well as web-based prediction 
programs (PolyPhen-2, SIFT, and MutationTaster). In step 5, variants remaining were 
searched further evaluated by reviewing existing literature and determining phenotypic 
match. Clinician scientists and geneticists, who had knowledge of the clinical 
phenotypes and pedigree structure, as well as experience with exome evaluation 
performed mutation calling. Remaining variants were confirmed in original patient DNA 
by Sanger sequencing as previously described. Whenever parental DNA was available, 
segregation analysis was performed.  
In a second evaluation process, variants in all 117 genes (Suppl. Table 2) that are 
known monogenic, recessive causes of renal ciliopathies (Gee, 2014) and may 
phenocopy the clinical presentation of NC/NL were systematically evaluated. In the third 
evaluation process, variants in 17 novel candidate genes for NL/NC (Gee, 2016) were 
systematically evaluated. These genes were ADCY6, CHD1, CLDN2, CLDN10, 
CLDN14, DMP1, ENPP1, FETUB, GALNT3, ITPKC, KL, MGP, ORAl1, PHEX, 
SLC13A2, SPP1, UMOD (Gee, 2016) 
 
Web Resources 
UCSC Genome Browser, http://genome.ucsc.edu/cgi-bin/hgGateway; 
1000 Genomes Browser, http://browser.1000genomes.org; 
Ensembl Genome Browser, http://www.ensembl.org; 
Exome Variant Server, http://evs.gs.washington.edu/EVS; 
Exome Aggregation Consortium, exac.broadinstitute.org; 
Online Mendelian Inheritance in Man (OMIM), http://www.omim.org; 
Clinvar https://www.ncbi.nlm.nih.gov/clinvar/ 
Biobase https://www.qiagenbioinformatics.com/products/human-gene-mutation 
Polyphen2, http://genetics.bwh.harvard.edu/pph2; 
Sorting Intolerant From Tolerant (SIFT), http://sift.jcvi.org/ 
MutationTaster http://www.mutationtaster.org/   
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RESULTS 
We performed WES in 54 individuals from 41 families with nephrolithiasis and/or 
nephrocalcinosis on renal ultrasound who manifested before the age of 25 years. These 
families had isolated NL/NC or a combination of both along with or without 
hypercalciuria. Of the 54 individuals, 27 had isolated NL, 16 had isolated NC, and 11 
had both NL/NC. No affected individual had hypercalciuria without NL or NC (Suppl. 
Fig. 2). When evaluating WES data for 30 genes (Suppl. Table 1) known to cause NL 
or NC when mutated, we identified a mutation in 10 of 41 families (24.3%) (Fig. 1) 
Recessive or dominant causative mutations were detected in 7 genes (Table 1). 
Pathogenic mutations were detected in 11 individuals from 7 families in 6 genes: 
GRHPR (2 individuals), AGXT (3 individuals), SLC12A1 (1 individual), ATP6V1B1 (1 
individual), CLDN19 (3 individuals), SLC34A1 (1 individual) (Table 1, Part A).  
Pathogenic mutations were detected in 5 individuals in 2 dominant genes: SLC9A3R1 
(1 individual) and SLC34A1 (4 individuals) (Table 1, Part B). SLC34A1 gene mutations 
may follow an autosomal recessive mode of inheritance causing infantile hypercalcemia 
(Konrad, 2015) or an autosomal dominant mode of inheritance causing nephrolithiasis 
(Prie, 2002). Of the 16 individuals in whom we detected causative mutations, 6 
presented with NL and 10 presented with NC on a renal ultrasound (Fig. 2).  
Five of 14 detected mutations (35.7%) were novel pathogenic variants that have not 
been previously reported in databases of human disease causing mutations. 
(https://portal.biobase-international.com/hgmd/pro/search_gene.php) 
Detection rate of causative mutations was not different between sexes. (10/26 in males 
and 6/28 in females, p = 0.17). Median age of onset was significantly lower (Z score: 
2.6, p= 0.009) in patients with a monogenic cause (3 yrs) versus those without (7 yrs) 
(Suppl. Fig 3). We evaluated our cohort for differences regarding disease (NL/NC) at 
presentation, age of onset of disease, and causative mutation detection (Fig. 3). We 
observed that individuals with NC presented before age 15 yrs, whereas individuals with 
NL presented from 0-25 years. Causative mutations were detected in 10/23 NC 
individuals and in 5/31 NL individuals (Fig. 3). 
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We evaluated age of onset of disease for each gene mutation detected in this cohort to 
the ones we previously published (Halbritter, 2015; Braun 2016) (Fig.4). Age of onset 
for mutations was very consistent for the following recessive genes SLC12A1 (age of 
onset < 1 yr), ATP6V1B1 (age of onset 5-7 yrs), SLC34A1 (age of onset was 0-3 yrs). 
Individuals with mutations in 2 dominant genes in all three cohorts presented after 1 
year of age.  
In 5 of the 15 families (33%) with multiple affected individuals included in our cohort we 
detected a causative genetic mutation, whereas in only 5 of the 32 (15.6%) families with 
single affected individuals a causative mutation was detected.  
WES data of 31 unsolved families were evaluated for mutations in 117 genes known to 
represent phenocopies of NL or NC. This included genes causing renal ciliopathies and 
tubulopathy (Suppl. Table 2). These genes if mutated may cause phenocopies of NC 
as they cause increased echogenicity on renal US (Gee, 2014). Among these 
phenocopy genes (Suppl. Table 2), we detected a homozygous frameshift, previously 
reported mutation in CTNS gene (Besouw, MT) in one patient with nephrocalcinosis 
(Table 1, Part C). This homozygous CTNS mutation was located in a homozygous 
peak. (Suppl Fig. 4).  
 
We generated a list of 17 hypothetical novel candidate genes (Gee, 2016) and 
evaluated WES data of 41 families for these genes, and detected no mutation.  
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DISCUSSION 
 
MUTATION DETECTION PERCENTAGE 
Here, we performed WES in 54 individuals from 41 families with NL or NC with onset 
before 25 years of age. We identified a causative mutation in 10 of 41 families (24.3%) 
in one of 30 genes known to cause monogenic NL/NC. Our results confirm our previous 
findings when identifying a monogenic cause of NL/NC in 15% of all subjects (20.8% 
children and 11% adults) in a separate mixed adult and pediatric cohort using targeted 
sequencing panels (Halbritter, 2015). Our findings are also similar to the previous panel 
based identification of a monogenic cause of NL/NC in 16.7% of children below the age 
of 18 years in a three-center cohort (Braun, 2016). We here choose WES because for 
an increasing number of potentially causative genes and phenocopies targeted 
sequencing panels have severe limitations. 
So far, WES has not been applied to patients with NL/NC. As we identified the disease-
causing mutation in about one quarter of families with NL/NC, our data show that WES 
is an efficient tool for molecular diagnostics in this disease group. 
 
PHENOCOPIES 
We evaluated 31 families without a molecular diagnosis in 30 NL/NC genes for 
mutations in phenocopy genes. About 117 genes that are known to cause recessive 
renal ciliopathies or tubulopathies have been shown to represent phenocopies of NC 
because of renal US findings of increased echogenicity (Braun, 2016). In our cohort, in 
one family with NC and chronic kidney disease, we detected a mutation in a phenocopy 
gene (CTNS) that causes nephropathic cystinosis. This molecular genetic diagnosis 
was not suspected clinically since the affected individual did not present with all classic 
features of cystinosis disease at initial presentation. Therefore, in this respective 
individual, the molecular diagnosis differed from the initial clinical diagnosis, 
demonstrating that WES helps to distinguish between NL/NC and other kidney diseases 
that phenocopy the presentation of NC on renal ultrasound This can be particularly 
advantageous in very early stages of disease progression, in which additional 
10 
 
characteristic symptoms might not yet be present, as well as in very rare genetic 
syndromes. The ability to evaluate a large number of phenocopy genes underlines an 
additional benefit of WES. Mutation detection is not restricted to a limited subset of 
monogenic diseases that were suspected based on the clinical presentation, but allows 
taking a broader spectrum of monogenic causes into consideration.  
In addition, we evaluated WES data for 17 hypothesized potential new NL/NC candidate 
genes in all 41 families, but did not detect any mutations (Gee, 2016).  
HIGH MUTATION DETECTION RATE 
The percentage of individuals with NL/NC, in whom a causative mutation was detected 
in this study and the two previous ones (Halbritter 2015, Braun 2016) may be subject to 
a certain bias toward severe cases, since individuals were recruited from specialized 
tertiary renal stone clinics.  
GENOTYPE-PHENOTYPE CORRELATION 
Although, the sample size is limited in this study, our findings confirm that early onset 
and familial prevalence are indicators of inherited disease as we have shown previously 
(Halbritter, 2015). In this study, we showed that median age of onset (3 yrs) was lower 
in individuals with a molecular genetic diagnosis in comparison to those without a 
genetic diagnosis (7 yrs). Additionally, mutation detection rate was higher in families 
with multiple affected individuals (33% multiple affected vs 19% single affected).  
 
None of the 5 individuals in whom a mutation in a dominant gene was identified 
presented before the age of 1 year. This is consistent with the finding that dominant 
monogenic causes typically manifest later in life as shown in our previous study (Braun, 
2016). We also compared age of onset of disease for each specific mutation detected in 
this study to previous published data from Braun, 2016, Halbritter 2015 (Fig 4). For 
example, the median age of onset from all three studies was 6.5 yrs for ATP6V1B1 
gene, which is higher than expected for mutations in ATP6V1B1, which causes dRTA 
and deafness. However, on further analysis we observed that all ATP6V1B1 mutations 
in 3 studies were missense mutations that may manifest later in life, in comparison to 
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truncating mutations, which present early in life.  
SLC34A1 
We identified mutations in SLC34A1 in 5 individuals from 2 families (Table 1). The 
individual harboring recessive mutations exhibited nephrocalcinosis, hypercalcemia, 
hypercalciuria, and hypophosphatemia consistent with renal phosphate wasting. On the 
other hand, affected individuals bearing dominant mutations had isolated 
nephrocalcinosis or hypercalciuria. Upon reviewing all published pediatric cases with 
SLC34A1 mutations (Table S3), the phenotypic spectrum observed mirrors our findings. 
All cases exhibit nephrolithiasis or nephrocalcinosis. However, recessive cases typically 
exhibit hypercalcemia, hypercalciuria, and hypophosphatemia whereas dominant 
disease virtually never includes hypercalcemia (Table S3, S4). Moreover, there is also a 
dichotomy between reported recessive and dominant cases based on age of onset, as 
recessive cases typically present in infancy (median 0.25 years) whereas dominant 
cases tend to present later in childhood (median 3.5 years) (Table S4, Suppl. Fig 5).  
 
CLINICAL IMPLICATIONS 
A molecular genetic diagnosis may have implications for both the affected individual and 
unaffected family members. As addressed in Table 2, following identification of certain 
causative mutations in affected individuals, the resulting knowledge might have 
important prophylactic implications for primary prophylaxis (stone recurrence) and 
secondary prophylaxis (loss of renal function) for affected and currently unaffected 
family members. Information resulting from mutation analysis will guide clinicians to 
monitor individuals for development of disease and to institute preventative treatment 
when possible. For example, individuals identified with recessive SLC34A1 mutations 
may benefit from phosphate supplementation to prevent hypercalcemia, hypercalciuria 
and nephrocalcinosis (Schlingmann, Konrad 2014). Similarly, individuals with recessive 
mutations in ATP6V1B1 and CLDN19 may benefit from hearing and ophthalmology 
testing respectively, and from early treatment for growth retardation and ESRD 
prevention. Individual (B969), who has a SLC9A3R1 mutation will benefit from close 
monitoring and treatment for hypophosphatemia. Recessive AGXT mutations detected 
in one sibling with severe hyperoxaluria and another sibling with a milder phenotype 
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(B1468) may allow early chronic kidney disease preventative care for the latter sibling. 
We also detected a recessive mutation in CTNS in an individual who presented with an 
incomplete cystinosis phenotype at time of presentation, which aided in providing 
disease specific treatment and delaying progression to ESRD. Therefore, we suggest 
“Practical Implications” (Table 2) for each gene in which we detected a likely disease-
causing mutation 
 
FUTURE DIRECTIONS/LIMITATIONS 
30 of 41 families in our cohort (73%) remained without a molecular diagnosis after 
WES.  In recessive monogenic diseases about 85% of all causative mutations are 
located within the coding sequence or the adjacent splice sites. The remaining 15% 
however, may represent genetic variants that are difficult to detect by WES such as 
complex deletion-insertion variants, copy-number variants, or may reside within a 
promotor and other intronic region. As WES can detect none of these variants, this 
technical limitation might explain why some cases remain without a molecular diagnosis 
after WES. In addition, causative mutations may be missed because the stringent 
criteria that we currently use to assess for deleteriousness may not include mild, 
hypomorphic mutations.  Furthermore, WES might miss a subset of causative variants 
due to low coverage in the respective target region.  
We here present WES as a rapid and reliable tool for molecular diagnostics in 
individuals with a history of at least one renal stone or NC on a renal ultrasound in 24% 
of affected individuals. This represents a major advance in providing a specific etiologic 
diagnosis in NL/NC, delaying progression to CKD/ESRD, and enabling personalization 
of the treatment plan for each stone former.  
CONCLUSION 
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FIGURE LEGENDS AND TITELS 
 
Figure 1. Flow diagram on detection of causative monogenic mutations by WES 
in 41 families with NL/ NC. 
A causative mutation was detected in 10 of 41 families (24.3%). A causative mutation 
was detected in the phenocopy gene (CTNS) in one patient with nephrocalcinosis.  
 
Figure 2. Renal ultrasound images of patients with NC, in whom causative 
mutations were detected.   
(A) Image from B1437_21 (SLC34A1). (B) Image from B1121 (ATP6V1B1). (C) Image 
from B1301_21 (SLC34A1) (D) Image from A4283 (CLDN19). (E) Image from B785 
(CTNS) (F) Image from B986_21 (SLC34A1).  
 
Figure 3. Distribution of number of affected individuals with NL/NC by age of 
onset.  
In a total of 16/54 (30%) affected individuals, a causative mutation was detected. 6/16 
(37.5%) affected individuals presented with NL, and 10/16 affected individuals (62.5%) 
presented with NC.  
 
Figure 4. Distribution of age of first diagnosis of NL/NC for each mutated gene 
detected by WES in 16 individuals from 10 families with NL/NC in this paper (filled 
circles), and from 9 families in Braun, 2016 (hollow squares), and from 5 families 
in Halbritter, 2015 (hollow triangles).  
Medians are depicted as black horizontal lines. Gene symbols are given on the X-axis   
for dominant genes (red), and for recessive genes (black). Note that age of onset of 
disease for mutated recessive genes SLC12A1, ATP6V1B1, SLC34A1 is similar in all 
three publications. SLC12A1, Solute carrier family 12 (sodium/potassium/chloride 
transporter) member 1, SLC34A1, Solute carrier family 34 (Type II Sodium/Phosphate 
cotransporter) member 1; GRHPR, Glyoxalate Reducatse/Hydroxypyruvate Reducatse; 
AGXT, Alanine-Glyoxalate Aminotransferase; ATP6V1B1, ATPase, H+ transporting, 
lysosomal, 56/58-KD, V1 subunit B, isoform 1; SLC9A3R1, Solute Carrier Family 9, 
Member 3, Regulator 1; CLDN19, Claudin 19 
 Table 1, Part A: Monogenic causative mutations of 6 recessive genes detected in 7 of 41 families with NL/NC. Mutated genes and related disease (OMIM 
nomenclature) are shown in sub headers to the table 
 
AGXT, Alanine-Glyoxalate aminotransferase; ATP6V1B1 (ATPase, H+ transporting, Lysosomal, 56/58-KD, V1 Subunit B, Isoform 1), BS1, Bartter syndrome Type 
1; CKD, chronic kidney disease; CLDN19, CLAUDIN 19; DRTAD, distal renal tubular acidosis with progressive deafness; F, female; het, heterozygous; GRHPR 
Glyoxalate Reductase/Hydroxypyruvate Reducatse; Hom, homozygous; HOMG5, Hypomagnesemia 5, Renal, With Ocular Involvement; (OMIM # 248190), M, Male; 
NA, Not applicable; NC, nephrocalcinosis; NPHLOP1, NEPHROLITHIASIS/OSTEOPOROSIS, HYPOPHOSPHATEMIC, 1 (OMIM # 612286); NL, nephrolithiasis; 
PH, primary hyperoxaluria; PH1, primary hyperoxaluria type 1; PH2, primary hyperoxaluria type 2; PPh2, polyphen-2; RTA, renal tubular acidosis; SLC12A1 (Solute 
carrier family 12 , SLC34A1, Solute carrier family 34.  
a
Different mutations at this position are reported 
Individual 
Nucleotide 
change 
Amino acid change 
State 
 
PPh2 
Evolutionary 
conservation 
      Ref.   Ethnicity (Sex) Age of Onset            NL/NC 
GRHPR, Primary Hyperoxaluria Type II 
 
B35-21 
 
 B35-22 
 
c.103del 
c.404+5G>A 
c.103del 
c.404+5G>A 
p.Asp35Thrfs*11 
splice site 
p.Asp35Thrfs*11 
splice site 
het  
het  
het   
het 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
Y (Cramer, 99) 
Y (Hopp, 2015) 
Y (Cramer, 99) 
Y (Hopp, 2015) 
Caucasian (M) 
Caucasian  (M) 
Caucasian  (M) 
Caucasian  (M) 
 
0.08 
0.08 
3 
3 
NL/NC 
NL/NC 
NL/NC 
NL/NC 
 
AGXT, Primary Hyperoxaluria Type I 
 
 
B1468-21 
 
  B1468-24 
 
 
B1230_21 
 
    c.1079G>C 
c.121G>A 
c.1079G>C 
c.121G>A 
 
c.731T>C 
p.Arg360Pro 
p.Gly41Arg 
p.Arg360Pro 
p.Gly41Arg 
 
p.Ile244Thr 
het  
het  
het   
het 
 
hom 
    1 
0.99 
1 
0.99 
 
0.4 
       C. elegans 
D. melanogaster 
C. elegans 
D. melanogaster 
 
M. musculus 
Novel
a 
Y (Danpure, 99) 
Novel
a 
Y (Danpure, 99) 
 
Y (Von, 97) 
       Arabic(M) 
Arabic  (M) 
Arabic  (F) 
Arabic  (F) 
 
Egyptian (M) 
           6 
6 
2.5 
2.5 
 
1 
           NL/NC 
NL/NC 
NC 
NC 
 
NL 
SLC12A1, Bartter Syndrome type 2 
 
 
B917-21 
 
c.769G>A 
c.1424G>A 
p.Gly257Ser 
p.Cys475Tyr 
het  
 het  
1 
0.99 
C. elegans 
D. melanogaster 
Y (Adachi, 2007) 
Novel 
Caucasian (M) 
Caucasian (M) 
 
1 
1 
NL/NC 
NL/NC 
ATP6V1B1, Renal Tubular acidosis with deafness 
 
 
B1121 c.242T>C p.Leu81Pro Hom 1 C. elegans Y (Karet, 99) Macedonian (M) 
 
1.7 NC 
 
CLDN19, Hypomagnesemia/renal/ophthalmological abnormalities 
 
 
A4283_21 
A4283_22 
A4283_23 
 
c.535G>A 
c.535G>A 
c.535G>A 
 
p.Gly179Ser 
p.Gly179Ser 
p.Gly179Ser 
Hom 
Hom 
Hom 
0.99 
0.99 
0.99 
D. rerio 
D. rerio 
D. rerio 
 
Novel 
Novel 
Novel 
South Asian (F) 
South Asian (M) 
South Asian (M) 
 
11 
5 
4 
NC 
NC 
NC 
 
SLC34A1, Infantile hypercalcemia/hypophosphatemia/nephrolithiasis 
 
B1437-21 
 
c.644+1G>A 
c.1204G>C 
Splice site 
p.Gly402Arg 
het 
het 
NA 
1 
NA 
D. rerio 
Y (Schlingmann, 
2016) 
Novel 
 
Arabic (M) 
Arabic (M) 
 
3 
3 
NC 
NC 
Table 1, Part B: Monogenic causative mutations in 2 dominant genes in 3 of 41 families with NL/NC. Mutated genes and related 
diseases (OMIM nomenclature) are shown in sub-headers to table 
  
 
F, female; het, Heterozygous; M, Male; NC, nephrocalcinosis; NL, nephrolithiasis; NPHLOP1, Nephrolithiasis/osteoporosis, hypophosphatemic, 1; 
NPHLOP2, Nephrolithiasis/osteoporosis, hypophosphatemic, 2; PPh2, polyphen-2  http://genetics.bwh.harvard.edu/pph2/; SLC9A3R1 (Solute 
carrier family 9, member 3, regulator 1); SLC34A1, Solute carrier family 34 
 
 
 
 
 
 
 
 Individual 
Nucleotide 
change 
Amino acid 
change 
Sta
te 
PPh2 
Evolutionary 
conservation 
Reference 
 
Ethnicity  
(Sex) 
Age of onset 
(yr) 
NL/NC 
 
SLC34A1, Infantile Hypercalcemia/Hypophosphatemia/Nephrolithiasis 
 
B1301_21 
B1301_22 
 
B986_21 
B986_22 
 
 
c.398C>T 
c.398C>T 
 
c.536T>C 
c.536T>C 
 
p.Ala133Val 
p.Ala133Val 
 
p.Leu179Pro 
p.Leu179Pro 
 
het 
het 
 
het 
het 
 
0.99 
0.99 
 
1 
1 
 
C. intestinalis 
C. intestinalis 
 
C. intestinalis 
C. intestinalis 
 
Y (Lapointe, 06) 
Y (Lapointe, 06) 
 
Novel 
Novel 
 
 
Macedonian (F) 
Macedonian (M) 
 
Caucasian (F) 
Caucasian (F) 
 
6.5 
10.5 
 
1.5 
1.5 
 
NC 
NC 
 
NC 
NC 
 
 
SLC9A3R1, Nephrolithiasis/osteoporosis 
 
B969-21 
 
c.673G>A 
 
p.Glu225Lys 
 
het 
 
0.82 
 
D. rerio 
 
Y (Karim,2008) 
 
Caucasian (F) 
 
7 
 
NL 
Table 1, Part C. Monogenic causative mutations in 1 phenocopy gene in 1 of 41 families with NL/NC. Mutated gene and related 
diseases (OMIM nomenclature) are shown in sub-headers to table 
  
 
HOM, homozygous; M, Male; NC, nephrocalcinosis; PPh2, polyphen-2 http://genetics.bwh.harvard.edu/pph2/ 
 
 
 
 
 
 
 
 Individual 
Nucleotid
e change 
Amino acid 
change 
State PPh2 
Evolutionary 
conservation 
Reference 
 
Ethnicity  
(Sex) 
Age of 
onset (yr) 
NL/NC 
CTNS (Cystinosin) 
 
 
B785 
 
c.[828_82
9insA] 
 
 
 
p.[Thr277fs] 
 
 
 
HOM 
 
 
NA 
 
 
NA 
 
Besouw, 2012 
 
 
Arabic (M) 
 
 
 
2 
 
 
 
NC 
Table 2: Clinical implications following detection of a monogenic cause of 
NL/NC. 
 
 
 
 
 
AGXT, Alanine-Glyoxalate Aminotransferase; ATP6V1B1, ATPase, H+ transporting, lysosomal, 56/58-KD, V1 Subunit B, Isoform 1; 
CLDN19, Claudin 19; CTNS, Cystinosis;  GC, genetic counseling; NC, nephrocalcinosis; NL, nephrolithiasis, SLC34A1, solute 
carrier family 34; SLC9A3R1, solute carrier family 9, member 3, regulator 1  
 
  
 
Gene  
(Family number) 
Clinical 
diagnosis 
(Pre-
screening) 
Genetic diagnosis 
(Post-screening) 
Practical implications  
(following genetic diagnosis) 
ATP6V1B1 
(B1121) 
        NC Distal renal tubular acidosis, 
deafness 
GC, 
 Hearing test, 
Metabolic correction, 
Growth retardation prevention, 
ESRD progression prevention 
SLC9A3R1 
(B969) 
NL Nephrolithiasis, 
osteoporosis, 
hypophosphatemia 
GC,  
Screening for hypophosphatemia, 
Screening for abnormal bone density,  
Osteoporosis prevention  
CLDN19  
(A4283) 
NC Hypomagnesemia 5, renal 
with ocular disease 
GC, 
Ophthalmology test, 
Treatment with magnesium 
AGXT  
(B1468) 
NL Primary hyperoxaluria GC, 
Consider pyridoxine trial, 
Consider RNAi treatment study in for 
future stone prevention 
 
SLC34A1  
(B1427) 
NC Hypercalcemia, infantile, 
type 2 
GC, 
Phosphate supplementation  
CTNS 
(B785) 
NC Cystinosis GC, 
Cysteamine therapy, 
Metabolic correction,  
Growth retardation prevention, 
ESRD progression prevention 
Diagnosis of NL, AND/OR NC 
on renal ultrasound:  
41 families (100%) 
Solved for 
mutation in 
phenocopy 
gene 
1 family 
Not solved for 
mutation in 
phenocopy 
gene 
 30 families 
Recessive 
mutations 
7/10 
families 
(70%) 
Dominant 
mutations 
3/10 
families 
(30%) 
Cases solved for 
genes known to 
cause NL:  
10 families 
(24.3%) 
Cases not solved for 
genes known to 
cause NL:  
31 families 
(75.6%) 
Whole Exome 
Sequencing 
  
Figure 1 
A B 
C D 
E F 
Figure 2 
Figure 3 
Figure 4 
Phenotype Match, Literature review 
Genotype/Phenotype Match, Literature review 
Keep Likely deleterious for protein function 
 
Evaluation for all 30 genes known to cause 
Nephrolithiasis 
Reject synonymous or intronic variants not located in 
within splice site 
Reject common SNP (MAF>1%) (Hg 19) 
 
Protein-truncating, highly conserved residue across phylogeny 
Predicted to be deleterious based on prediction scores 
 
Supplementary Figure 1: Variant filtering process for the identification of the causative 
mutation in genes known to cause nephrolithiasis (NL). Schematic overview of the workflow that 
was used for filtering of WES data in all families. i) Exclusion of all variants that are present with a 
minor allele frequency (MAF)>1% in healthy control cohorts (1000 Genomes). ii) Exclusion of 
synonymous variants and all intronic variants that are not located within splice sites. iii) Keep all 
variants detected in known NL genes  iv) Ranking of remaining variants based on their predicted 
likelihood to be deleterious for the function of the encoded protein. v) Reviewing literature and 
delineating whether the detected mutation matches the phenotype. 
Accept causative known/novel mutation in known 
NL/NC genes 
Nephrolithiasis 
22 
 
 
 
 
Nephrocalcinosis 
12 
 
 
Hypercalciuria  
8 
3 
5 
4 
Supplementary Fig 2. Description of cohort based on diagnosis. 
Number of patients who first presented with isolated NL = 2, 
isolated NC = 12. No patient had isolated hypercalciuria.   
Supplementary Figure 3: Median age of onset in individuals with 
a monogenic cause of NL (age 3 yrs) was significantly lower than in 
those without a monogenic cause (age 7 yrs). (Mann Whitney U 
test, Z score = 2.6,  p = 0.009)  
Supplementary Figure 4: (A) Homozygozity mapping of B785. 
The CTNS mutation was located in the homozygous peak of 
chromosome 17.  
(B) Sanger sequencing trace showing insertion of nucleotide A. 
(C) Renal ultrasound of B785 showing nephrocalcinosis 
A 
B C 
Supplementary Figure 5. Age of onset versus mode of 
Mendelian SLC34A1 Inheritance in 30 individuals in whom a 
monogenic cause of nephrolithiais/nephrocalcinosis was 
detected.  
Supplementary Table 1. 30 genes that are known to cause monogenic forms of NL/NC and that were included in the study 
 
 
Gene Symbol Gene Name Accession # Disease entity 
MIM-
Phenotype # 
Mode 
Coding 
Exons 
Reference 
1 AGXT 
Alanine-glyoxylate 
aminotransferase 
NM_000030.2 
Primary hyperoxaluria, type 1 
259900 AR 11 Purdue, 1999 
2 APRT 
Adenine 
phosphoribosyltransferase 
NM_000485.2 
Adenine phosphoribosyltransferase 
deficiency, 
Urolithiasis (DHA stones), renal failure 
614723 AR 5 Hidaka, 1987 
3 ATP6V0A4 
ATPase, H+ transporting, 
lysosomal V0 
subunit a4 
NM_020632.2 
dRTA 
602722 AR 20 Smith, 2000 
4 ATP6V1B1 
ATPase, H+ transporting, 
lysosomal 
56/58kDa, V1 subunit B1 
NM_001692.3 
Distal renal tubular acidosis (dRTA) 
with deafness 267300 AR 14 Karet, 1999 
5 CA2 Carbonic anhydrase II NM_000067.2 Osteopetrosis + d/pRTA 259730 AR 7 Venta, 1991 
6 CASR Calcium-sensing receptor NM_001178065.1 
Hypocalcemia with Bartter syndrome / 
hypocalcemia, autosomal dominant 
601198 AD 6 Pearce, 1996 
7 CLCN5 
Chloride channel, voltage-
sensitive 5 
NM_001127898.3 
Dent disease / Nephrolithiasis, type 1 300009 / 
310468 
XR 14 Lloyd, 1996 
8 CLCNKB 
Chloride channel, voltage-
sensitive Kb 
NM_000085.4 
Bartter syndrome, type 3 
607364 AR 19 Simon, 1997 
9 CLDN16 Claudin 16 NM_006580.3 
Familial hypomagnesemia with 
hypercalciuria & 
nephrocalcinosis, FHHNC 
248250 AR 5 Simon, 1999 
10 CLDN19 Claudin 19 NM_001123395.1 
Familial hypomagnesemia with 
hypercalciuria & 
nephrocalcinosis with ocular 
abnormalities 
248190 AR 4 Konrad, 2006 
11 CYP24A1 
Cytochrome P450, family 24, 
subfamily 
A, polypeptide 1 
NM_000782.4 
1,25-(OH) D-24 hydroxylase deficiency 
,infantile 
Hypercalcemia 
143880 AR 11 
Schlingmann, 
2011 
12 FAM20A 
Family with sequence similarity 
20, 
member A 
NM_017565.3 
Enamel-Renal syndrome, 
amelogenesis imperfecta 
and nephrocalcinosis 
204690 AR 12 
Jaureguiberry, 
2012 
13 GRHPR 
Glyoxylate 
reductase/hydroxypyruvate 
reductase 
NM_012203.1 
Primary hyperoxaluria, type 2 
260000 AR 9 
Cramer,  
1999 
14 HNF4A 
Hepatocyte nuclear factor 4, 
alpha 
NM_000457.4 
MODY + Fanconi syndrome + 
Nephrocalcinosis 
125850 AD 1 
Hamilton, 
2014 
15 HOGA1 
4-hydroxy-2-oxoglutarate 
aldolase 1 
NM_138413.3 
Primary hyperoxaluria, type 3 
613616 AR 7 
Belostotsky, 
2010 
16 HPRT1 
Hypoxanthine 
phosphoribosyltransferase 1 
NM_000194.2 
Kelley-Seegmiller syndrome, partial 
HPRTdeficiency, HPRT-related gout 
300323 XR 9 
Davidson, 
1991 
17 KCNJ1 
Potassium inwardly-rectifying 
channel, 
subfamily J, member 1 
NM_000220.4 
Bartter syndrome, type 2 
241200 AR 2 
Simon,  
1996 
18 OCRL 
Oculocerebrorenal syndrome of 
Lowe 
NM_000276.3 
Lowe syndrome / Dent disease 2 309000 / 
300555 
XR 24 Reilly, 1988 
19 SLC12A1 
Solute carrier family 12, member 
1 
NM_000338.2 
Bartter syndrome, type 1 
601678 AR 27 Simon, 1996 
20 SLC22A12 
Solute carrier family 22 (organic 
anion/urate transporter), 
member 12 
NM_144585.3 
Renal hypouricemia, RHUC1 
220150 AD/AR 10 
Enomoto, 
2002 
21 SLC26A1 
Solute carrier family 26 (sulfate 
transporter), member 1 
NM_213613 
Nephrolithiasis, calcium oxalate 
167030 AR 4 Gee, 2016 
22 SLC2A9 
Solute carrier family 2 (facilitated 
glucose transporter), member 9 
NM_001001290.1 
Renal hypouricemia, RHUC2 
612076 AD/AR 13 Matuso, 2008 
23 SLC34A1 
Solute carrier family 34 (sodium 
phosphate), member 1 
NM_003052.4 
Hypophosphatemic 
nephrolithiasis/osteoporosis-1, 
NPHLOP1 / Fanconi renotubular 
syndrome 2 
612286 / 
613388 
AD/AR 13 Prie, 2002 
24 SLC34A3 
Solute carrier family 34 (sodium 
phosphate), member 3 
NM_001177316.1 
Hypophosphatemic rickets with 
hypercalciuria 241530 AR 12 
Lorenz-
Depiereux, 
2006 
25 SLC3A1 
Solute carrier family 3 (cystine, 
dibasic 
and neutral amino acid 
transporters, 
activator of cystine, dibasic and 
neutral 
amino acid transport), member 1 
NM_000341.3 
Cystinuria, type A 
220100 AR 10 
Calonge, 
1994 
26 SLC4A1 
Solute carrier family 4, anion 
exchanger, 
member 1 (erythrocyte 
membrane 
protein band 3, Diego blood 
group) 
NM_000342.3 
Primary distal renal tubular acidosis, 
dominant / 
recessive 179800 / 
611590 
AD/AR 19 Bruce, 1997 
27 SLC7A9 
Solute carrier family 7 
(glycoproteinassociated 
amino acid transporter light 
chain, bo,+ system), member 9 
NM_014270.4 
Cystinuria, type B 
220100 AD/AR 12 
Feliubadalo, 
1999 
28 SLC9A3R1 
Solute carrier family 9, subfamily 
A(NHE3, cation proton antiporter 
3),member 3 regulator 1 
NM_004252.4 
Hypophosphatemic 
nephrolithiasis/osteoporosis 2, 
NPHLOP2 
612287 AD 6 Karim, 2008 
29 VDR 
Vitamin D (1,25- 
dihydroxyvitamin D3) 
receptor 
NM_000376.2 
Idiopathic hypercalciuria 
277440 AD 11 Scott, 1999 
30 XDH Xanthine dehydrogenase NM_000379.3 Xanthinuria, type 1 278300 AR 36 Ichida,1997 
 
Supplementary Table S2. Nephrocalcinosis phenocopy panel of 117 genes. 
 
Disease Group Causative Genes 
Renal Ciliopathy 
genes 
NPHP1, INVS, NPHP3, NPHP4, IQCB1, CEP290, GLIS2, 
RPGRIP1L, NEK8, SDCCAG8, TMEM67, TTC21B, WDR19, 
ZNF423, CEP164, ANKS6, IFT172, CEP83, DCDC2, IFT81, 
TRAF3IP1, XPNPEP3, FAN1, PKHD1, INPP5E, TMEM216, 
AHI1, ARL13B, CC2D2A, KIF7, TCTN1, TMEM237, CEP41, 
TMEM138, C5orf42, TCTN3, TMEM231, CSPP1, PDE6D, 
KIAA0586, TCTN2, CEP104, KIAA0556, MKS1, B9D1, B9D2, 
KIF14, TMEM107, BBS1, BBS2, ARL6, BBS4, BBS5, MKKS, 
BBS7, TTC8, PTHB1, BBS10, TRIM32, BBS12, WDPCP, 
LZTFL1, BBIP1, IFT27, OFD1, DDX59, SCLT1, C2CD3, 
KIAA0753, IFT122, WDR35, IFT43, IFT80, DYNC2H1, NEK1, 
WDR60, IFT140, WDR34, CEP120, EVC, EVC2, IFT57, IFT52, 
ALMS1, ATXN10, POC1A, POC1B 
  
  
  
Renal 
Tubulopathies 
and 
Endocrinopathies  
SLC41A1, HNF1B, BSND, CLCNKB, AQP2, AVP, AVPR2, REN, 
CYP27B1, CYP2R1, HNF4A, SLC12A3, SLC4A4, UMOD, VDR, 
WNK4, XDH, SLC2A2, SLC6A19, SLC7A7, EGF, NR3C2, CTNS, 
TRPM6, KCNJ10, FXYD2, WNK1, SCNN1A, SCNN1G, SCNN1B 
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 Table S3. Phenotypic spectrum of previousl reported SLC34A1 mutations and ovel mutations reported in this current study 
Subject Inheritance Age of onset (Yrs) NC/NL HP HCU HCE Reference 
F1.1 Recessive 0.05 NC YES YES YES 1 
F1.2 Recessive 0.08 NC YES YES YES 1 
F3.1 Recessive 0.16 NC YES YES YES 1 
F12.1 Recessive 0.58 NC YES YES YES 1 
F7.1 Recessive 0.83 NC - YES YES 1 
F8.1 Recessive 0.08 NC YES YES YES 1 
F11.1 Recessive 0.33 NC YES - YES 1 
F14.1 Recessive 0.25 NC - YES YES 1 
B1437 Recessive 3 NC YES YES YES Current 
F2.1 Recessive 0.16 NC YES YES YES 1 
F6.1 Recessive 0.75 NC YES YES YES 1 
F9.1 Recessive 0.25 NC YES - YES 1 
F10.1 Recessive 0.25 NC YES YES YES 1 
F13.1 Recessive 0.5 NC YES - - 1 
F15.1 Recessive 1.5 NC - - - 1 
JCEM1 Recessive 1.5 NC YES YES YES 2 
JCEM2 Recessive 0.16 NC YES YES YES 2 
PN1 Recessive 0 NC - - - 3 
B168 Recessive 0.4 NC YES NA NA 4 
F4.1 Recessive 0.16 NC YES YES YES 1 
F5.1 Dominant 0.33 NC YES YES YES 1 
B491 Dominant 4 NL YES YES - 5 
B523 Dominant 3 NL YES YES - 5 
B484 Dominant 3 NL YES - - 5 
B610 Dominant 9 NL - YES - 5 
B417 Dominant 7 NL YES YES - 5 
B1301_21 Dominant 6.5 NC - YES - Current 
B1301_22 Dominant 10.5 NC - YES - Current 
B986_21 Dominant 1.5 NC - YES - Current 
B986_22 Dominant 1.5 NC - YES - Current 
Abbreviations: HCE, hypercalcemia; HCU, hypercalciuria; HP, hypophosphatemia; NA, no data available; NC, nephrocalcinosis; NL, 
nephrolithiasis 
 Table S4. Comparison of clinical features between recessive and dominant SLC34A1 cases. 
  
 
 
Mode of 
inheritance/ 
Hypercalcemia 
Recessive Dominant Total 
 
HC 16 1 17 
 
No HC 4 9 13 
 
Total 20 10 30 
     Odds ratio 36, p = 0.0027 (chi square test) 
 
